Evidence map›Paper›PMID 24129123›Full record

ReviewVaccine2013

Priorities for CMV vaccine development.

Philip R Krause, Stephanie R Bialek, Suresh B Boppana, Paul D Griffiths, Catherine A Laughlin, Per Ljungman, Edward S Mocarski, Robert F Pass, Jennifer S Read, Mark R Schleiss and 1 more

Abstract readReview
In one paragraph

Review in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 147 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  6. The immune response to human cytomegalovirus: impact of age, co-morbidities and the significance of anti-viral activity assessment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Cytomegalovirus urinary excretion in children with congenital and postnatally acquired infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2025
    Article
  12. Article
  13. A vaccine against cytomegalovirus: how close are we?The Journal of clinical investigation · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Philip R KrauseOffice of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, United States. Electronic address: philip.krause@fda.hhs.gov.
Stephanie R BialekCenters for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: zqg7@cdc.gov.
Suresh B BoppanaUniversity of Alabama, Birmingham, AL, United States. Electronic address: sboppana@peds.uab.edu.
Paul D GriffithsUniversity College London, UK. Electronic address: p.griffiths@ucl.ac.uk.
Catherine A LaughlinNational Institute of Allergy and Infectious Diseases, National Institutes of Health, United States. Electronic address: CLaughlin@niaid.nih.gov.
Per LjungmanKarolinska Institutet, Stockholm, Sweden. Electronic address: Per.Ljungman@ki.se.
Edward S MocarskiEmory University, Atlanta, GA, United States. Electronic address: mocarski@emory.edu.
Robert F PassUniversity of Alabama, Birmingham, AL, United States. Electronic address: RPass@peds.uab.edu.
Jennifer S ReadNational Vaccine Program Office, Washington, DC, United States. Electronic address: Jennifer.Read@fda.hhs.gov.
Mark R SchleissUniversity of Minnesota, Minneapolis, MN, United States. Electronic address: schleiss@umn.edu.
Stanley A PlotkinUniversity of Pennsylvania, Philadelphia, PA, United States. Electronic address: stanley.plotkin@vaxconsult.com.
University of Alabama at Birmingham · USCenter for Biologics Evaluation and Research · USCenters for Disease Control and Prevention · USEmory University · USKarolinska Institutet · SENational Institute of Allergy and Infectious Diseases · USUniversity College London · GBUniversity of Minnesota · USUniversity of Pennsylvania · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

A multidisciplinary meeting addressed priorities related to development of vaccines against cytomegalovirus (CMV), the cause of congenital CMV (cCMV) disease and of serious disease in the immunocompromised. Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the value of additional research. A universal childhood CMV vaccine could potentially rapidly reduce cCMV disease, as infected children are sources of viral transmission to seronegative and seropositive mothers. A vaccine administered to adolescents or adult women could also reduce cCMV disease by making them immune prior to pregnancy. Clinical trials of CMV vaccines in women should evaluate protection against cCMV infection, an essential precursor of cCMV disease, which is a more practical and acceptable endpoint for assessing vaccine effects on maternal-fetal transmission. Clinical trials of vaccines to evaluate prevention of CMV disease in stem cell transplant recipients could use CMV viremia at a level triggering pre-emptive antiviral therapy as an endpoint, because widespread use of pre-emptive and prophylactic antivirals has rendered CMV-induced disease too rare to be a practical endpoint for clinical trials. In solid organ transplant patients, CMV-associated disease is sufficiently common for use as a primary endpoint. Additional research to advance CMV vaccine development should include identifying factors that predict fetal loss due to CMV, determining age-specific incidence and transmission rates, defining the mechanism and relative contributions of maternal reactivation and re-infection to cCMV disease, developing assays that can distinguish between reactivation and re-infection in seropositive vaccinees, further defining predictors of sequelae from cCMV infection, and identifying clinically relevant immune response parameters to CMV (including developing validated assays that could assess CMV antibody avidity) that could lead to the establishment of immune correlates of protection.

Indexed as

CytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesHumansRisk FactorsVaccinationCytomegalovirus VaccinesClinical trial endpointsCongenital CMVCytomegalovirusMeeting reportViruses

Identifiers

PMID24129123
PMCPMC4623576
OpenAlexW2024346310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.